Association of Testosterone-Induced Neutrophil and Monocyte Elevation with Thromboembolic Risk: Insights from the TRAVERSE Trial
Highlights
- TRT significantly increases circulating neutrophil and monocyte counts, while decreasing lymphocytes and platelets in hypogonadal men with cardiovascular risk factors.
- Elevations in neutrophils and monocytes during TRT are associated with increased risk of venous thromboembolism (VTE) and major adverse cardiovascular events (MACE).
- Baseline and on-treatment neutrophil and monocyte counts serve as independent predictors of cardiovascular risk during TRT.
- Clinical monitoring of leukocyte subtypes should be integrated into the risk assessment of hypogonadal men undergoing TRT.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.